Lifitegrast sodium (C09-1142-308)

Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC 50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye diseaseIn VitroLifitegrast (SAR 1118) inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus lessening overall inflammatory responses. Lifitegrast strongly inhibits Jurkat T cell attachment to ICAM-1 with an IC 50 of 2.98 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoLifitegrast has potent anti-inflammatory activity on corneal inflammation induced by antibiotic-killed P. aeruginosa and S. aureus in the presence of a silicone hydrogel lens with the optimal application being a 1% solution applied either 2 or 3 times prior. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:αLβ2. Specifications and Purity: 99%. Molecular Formula: C29H23Cl2N2NaO7S. Molecular Weight: 637.46. PubChem CID: 56963348. Isomeric SMILES: CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)[O-])NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl.[Na+].